Authors

Latest:

Cancer Screening and Management: Overview of the Current Landscape

A panel of esteemed cancer experts explore the challenges and opportunities in cancer screening and identification, shedding light on the evolving landscape and its impact on clinical practice.

Betty Hamilton, MD

Latest:

Dr Hamilton on HRQOL Differences With Gilteritinib Vs Placebo in Post-Transplant FLT3-ITD+ AML

Betty Hamilton, MD, discusses quality of life differences between post-transplant gilteritinib vs placebo in FLT3-ITD–positive acute myeloid leukemia.

Bharat Patel, MBA

Latest:

Adequate Resources Are Key to Oncology Clinical Trial Success

With all the exciting developments occurring in cancer research, community oncology practices that currently do not offer clinical trials to patients may be considering executing a research program.

Bhavana Pothuri, MD

Bhavana Pothuri, MD, is a gynecologic oncologist and professor in the Department of Obstetrics and Gynecology at the NYU School of Medicine in New York.

Latest:

Dr Pothuri on Current Unmet Needs in Recurrent/Advanced Endometrial Cancer

Bhavana Pothuri, MD, discusses remaining unmet needs for patients with recurrent/advanced endometrial cancer.

Bianca D. Santomasso, MD, PhD

Latest:

Dr. Santomasso on Managing CNS Toxicity from CAR T-Cell Therapy for B-Cell Lymphoma

Bianca D. Santomasso, MD, PhD, discusses how she prevents central nervous system toxicity due to CAR T-cell therapy for aggressive B-cell lymphoma in her own practice.

Bijal D. Shah, MD

Latest:

Future Directions and Unmet Needs in Relapsed/Refractory MCL

A panel of experts discuss future directions and remaining unmet needs for patients with relapsed/refractory MCL.

Bijal D. Shah, MD, Anthony S. Stein, MD, Gehr Family Center for Leukemia Research

Bijal D. Shah, MD, H. Lee Moffitt Cancer Center & Research Institute

Bijal D. Shah, MD, Moffitt Cancer Center

Bijal Shah, MD, Moffit Cancer Center

Latest:

Ph+ ALL Management Updates: Expert Insights

Leading experts Bijal Shah, MD, MS, and Hagop Kantarjian, MD, discuss diagnostic challenges, evolving treatments, and prognosis in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Bijal Shah, MD H. Lee Moffitt Cancer Center & Research Institute

Latest:

The Potential Future Impact of CAR T Cell Therapy in Adult ALL

Experts in hematology oncology consider unmet needs for adult patients with relapsed/refractory ALL and reflect on the potential impact that FDA approval of CAR T cell therapy would have on the treatment landscape.

Bijal Shah, MD, Moffitt Cancer Center

Latest:

Treating Mantle Cell Lymphoma: A Look At ZUMA-2 Trial And KTE-X19

Bilal Piperdi, MD

Latest:

Dr. Piperdi Discusses RICTOR Amplification in Lung Cancer

Bilal Piperdi, MD, discusses an analysis presented at the 2014 ASCO Annual Meeting that looked at RICTOR amplification to define a subset of patients with lung cancer.

Bin Zheng, PhD

Latest:

Bin Zheng on the Potential of Diabetes Drugs in Melanoma

Bin Zheng, PhD, assistant professor of Dermatology at Harvard Medical School and assistant biologist at Massachusetts General Hospital, discusses the potential for phenformin, a drug created for Type 2 diabetes, to be used for patients with melanoma.

Bing Xia, MD

Latest:

Dr. Xia on the Frontline Treatment Landscape of ALK-Positive NSCLC

Bing Xia, MD, assistant professor of clinical medicine, Keck School of Medicine, University of Southern California, discusses the frontline treatment landscape of ALK-positive non–small cell lung cancer (NSCLC).

Binod Dhakal, MD

Latest:

BCMA Bispecifics in the Clinic: Data, Toxicities, and Real-World Experience

Panelists discuss how dual-targeting bispecific therapies, exemplified by JNJ-78934804 (targeting BCMA and GPRC5D), show early potential to redefine treatment paradigms in heavily pretreated multiple myeloma, with impressive response rates and manageable safety profiles.

Biological Sciences

Biotech News

Latest:

Age Cutoff for Pap Tests Questioned

More than 12% of newly diagnosed cervical cancers occurred in women aged 70 to 85 years during 2000 to 2006

Birte Wistinghausen, MD

Latest:

Dr. Wistinghausen on Developing Drugs for Children With Cancer

Birte Wistinghausen, MD, medical director of the Division of Pediatric Hematology-Oncology, the Kravis Children's Hospital and Icahn School of Medicine at Mount Sinai, discusses developing drugs for children with cancer.

Bita Fakhri, MD, MPH

Latest:

Looking Ahead: Novel Therapies and Future Perspectives in the Treatment of CLL

The panel concludes its discussion with a look to the future of CLL treatment, focusing on emerging novel agents and exciting clinical research.